Nanopore has raised $1.26B in funding, including key rounds such as $64.2M Post-IPO (2024), $84.5M Post-IPO (2023), and a major $270M Series H (2021) backed by investors like M&G, Temasek, Wellington, and Nikon. Founded in 2005, the company pioneered real-time nanopore sequencing technology and has since become a leader in molecular analysis and genomics. With significant backing from global biotech and institutional investors, Nanopore continues to scale its technology for clinical diagnostics, research, and industrial applications worldwide.